All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Jeffrey LancetThe AML Hub was pleased to speak with Jeffrey E. Lancet, Moffitt Cancer Center, Tampa, US. We asked, Which AML patients benefit most from treatment with CPX-351?
Which AML patients benefit most from treatment with CPX-351?
Lancet begins by describing factors that affect treatment choices for patients with AML, especially the patient goals. He outlines the use of CPX-351 as primary induction therapy, its challenges, benefits, and main candidates. Finally, Lancet discusses oral azacitidine and the changing landscape of AML therapies.
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?